Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 10Lymphoid 8Classical hematology 4Plasma cell 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Castrate Resistant Prostate Cancer (CRPC) 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × AP 1903 reagent × Genitourinary × Clear all
NCT02744287 2026-02-23

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Regeneron Pharmaceuticals

Phase 1 Terminated
52 enrolled
Genitourinary

Prostatic Neoplasms

NCT00868595 2019-10-08

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

Phase 1 Completed
18 enrolled
Genitourinary

Castrate Resistant Prostate Cancer (CRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡